Uso de injeção de toxina botulínica na redução da intensidade de dor miofascial e agregados plaquetários no rejuvenescimento facial, revisão sistemática e metaanálise

• Ano de defesa: 2020
• Autor(a) principal: Andrade, Carla Frehner
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Positivo; Brasil; Pós-Graduação; Programa de Pós-Graduação em Odontologia Clínica; UP
• Palavras-chave em Português: Odontologia; Toxinas botulínicas tipo A; Plasma rico em plaquetas; Rejuvenescimento; Revisão sistemática; Dor facial; CNPQ::CIENCIAS DA SAUDE::ODONTOLOGIA
• Link de acesso: https://repositorio.cruzeirodosul.edu.br/handle/123456789/2194

To evaluate, through two systematic reviews, the injection of botulinum toxin to reduce the intensity of myofascial pain, as well as the injection of platelet aggregates in facial rejuvenation in adult patients. In manuscript 1, the research sought studies that compared the use of botulinum toxin with other therapeutic techniques to reduce the intensity of myofascial pain. The searches were performed in PubMed, Cochrane Library, Scopus, Web of Science, Lilacs / BBO and Gray Literature. IADR abstracts, records of unpublished essays, dissertations and theses were also researched. The “Cochrane Collaboration” risk-bias tool was applied to assess the quality of the studies. A total of 4372 studies were identified, nine (9) remained in a qualitative study, eight (8) of these studies were considered to have an "unclear" risk of bias and only one study had a "low" risk of bias in the main domains. Only two (2) studies presented similar data to be included in the meta-analysis. Both studies evaluated pain relief using botulinum toxin (BTX-A) versus saline. In the study that compared botulinum toxin with other treatments, a meta-analysis was carried out, which showed that, after 3 months of follow-up, pain relief was 15.70 (95% confidence interval [CI] = 0, 80 to 30.61; p = 0.04). It was concluded that the BTX-A injection showed a reduction in the intensity of myofascial pain compared to saline in adults after 3 months, however more well-designed studies should be performed to verify the reduction of myofascial pain with the use of BTX - THE. In manuscript 2, the research sought randomized clinical trials that compared the use of platelet-rich plasma injection alone or associated with other facial rejuvenation techniques. The search was conducted in PubMed, Cochrane Library, Scopus, Web of Science, Lilacs / BBO and Gray Literature. IADR abstracts, records of unpublished essays, dissertations and theses were also researched. The “Cochrane Collaboration” riskbias tool was applied to assess the quality of the studies. 7137 articles were identified. Only four (4) studies remained in the qualitative synthesis, only one study had a low risk of bias and the others were considered to have an undefined risk of bias in the key domains. In conclusion, there are few studies in the literature that compare the use of platelet aggregates in facial rejuvenation and those that are available have a risk of "undefined" or "high" bias. There is a need for further clinical studies to compare the use of platelet aggregate injection associated or not with facial rejuvenation techniques.